NCE-1 Intelligence & Market Opportunity

Ojemda

Tovorafenib

Anticancer

Oral Suspension

Ojemda is the first FDA-approved targeted therapy for children 6 months and older with relapsed or treatment-resistant pediatric low-grade glioma (pLGG) caused by certain BRAF gene changes.

Approval Date

23-Apr-24

NCE-1 Date

23-Apr-28

NCE Date

23-Apr-29

Commercial snapshot

Market performance & projections

Revenue ($M)

155

CAGR (%)

-0.2047

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

103

2032

123

Molecule profile

Details & specifications

Molecule

Tovorafenib

Innovator

DAY ONE BIOPHARMACEUTICALS INC

Dosage Form

Oral Suspension

Strength

25 mg/mL

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory pediatric low-grade glioma

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.